HRD+Breast Cancer
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer (NCT05085626) | Tianjin Medical University Cancer Institute and Hospital | 2021-02-08 |
Track HRD+Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.